AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
The Spread of AI Discovery Deals Shows Biopharma Is Building an Ecosystem, Not Backing One Model
A cluster of recent partnership announcements suggests biopharma is constructing a layered AI discovery ecosystem rather than choosing a single dominant platform. That diversification reflects both scientific uncertainty and a growing belief that different AI tools will matter at different stages of R&D.
Lilly’s Insilico Pact Turns AI Drug Discovery Into Big-Pharma Procurement
Eli Lilly’s multibillion-dollar collaboration with Insilico Medicine is significant less for its headline size than for what it says about how large drugmakers now buy AI-enabled discovery capacity. The deal suggests AI platforms are no longer being evaluated as speculative innovation projects, but as sourcing channels for future drug candidates.
Tempus and Daiichi Sankyo Push AI Upstream Into ADC Design
Tempus and Daiichi Sankyo are teaming up on AI models for antibody-drug conjugate development, extending AI’s role from biomarker work into the design logic of one of oncology’s hottest drug classes. The collaboration matters because ADCs are complex, multimodal products where better target, linker, payload, and patient-selection decisions could materially improve success rates.
Takeda’s $1.7 Billion Iambic Bet Shows Big Pharma Still Pays for AI-Validated Small-Molecule Platforms
Takeda and Iambic Therapeutics have announced a deal worth up to $1.7 billion to advance small-molecule programs, adding another major validation point for AI-enabled drug discovery. The agreement suggests large pharma remains willing to spend heavily when platform claims are tied to tangible pipeline output rather than abstract model performance.
Recursion’s Roche Signal Highlights Big Pharma’s Ongoing Appetite for AI Discovery Platforms
New investor-focused coverage of Recursion Pharmaceuticals points to continued attention on Roche’s commitment to AI-enabled drug development. The story is less about short-term stock moves than about whether major pharma companies are moving from exploratory partnerships to sustained platform dependence.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.